Free Helpline
We are here to assist you.
Health Advisor
+91-8877772277Available 7 days a week
10:00 AM – 6:00 PM to support you with urgent concerns and guide you toward the right care.
We are here to assist you.
Health Advisor
+91-8877772277Available 7 days a week
10:00 AM – 6:00 PM to support you with urgent concerns and guide you toward the right care.
Understand ovarian cancer maintenance therapy, including its goals, types (PARP inhibitors, angiogenesis inhibitors), side effects, and how it helps prevent cancer recurrence after chemotherapy.
Receiving a diagnosis of ovarian cancer can bring about a whirlwind of emotions and questions. After completing initial treatments like chemotherapy, the focus often shifts to preventing the cancer from returning. This is where maintenance therapy comes into play. It's a strategy designed to keep ovarian cancer in remission for as long as possible, giving patients more time and peace of mind.
Think of maintenance therapy as a follow-up strategy after your primary cancer treatment. Its main goal is to minimize the risk of ovarian cancer recurrence. It's not about eliminating cancer that's still present, but rather about creating an environment that makes it harder for any remaining cancer cells to grow and multiply. The aim is to extend the period of remission, meaning the time when cancer is not detectable, and improve the overall quality of life for patients.
Your doctor typically recommends maintenance therapy after you've successfully completed a course of chemotherapy for ovarian cancer. This is especially common in cases of advanced stage (Stage 3 or 4) ovarian cancer. It might also be suggested if your cancer has returned (recurrent ovarian cancer) but has shown a positive response to platinum-based chemotherapy. The decision is highly personalized, taking into account the specific type of ovarian cancer, its stage, your response to previous treatments, and your overall health.
For example, imagine a patient, Mrs. Sharma, who has just finished her chemotherapy for Stage 3 ovarian cancer. Her scans show no signs of the disease. Her oncologist discusses maintenance therapy with her, explaining that it's a way to significantly reduce the chances of the cancer coming back in the near future, offering her a better outlook.
The Food and Drug Administration (FDA) has approved several types of medications for ovarian cancer maintenance therapy. The most common ones fall into two main categories:
How they work: Your cells have natural repair mechanisms to fix damaged DNA. The PARP enzyme plays a vital role in repairing DNA damage, especially in cancer cells. PARP inhibitors are drugs that block this enzyme. When PARP is blocked, cancer cells with damaged DNA cannot repair themselves and eventually die. This is particularly effective in ovarian cancers that have certain genetic mutations, like BRCA mutations, which already impair DNA repair.
How they are taken: These are usually oral medications, meaning you take them as pills. Depending on the specific PARP inhibitor prescribed, you might take them once or twice a day. They can often be taken with or without food.
FDA-approved PARP inhibitors for ovarian cancer include:
How they work: Tumors need a blood supply to grow and survive. Angiogenesis is the process by which new blood vessels are formed. Angiogenesis inhibitors are a class of drugs that prevent tumors from creating new blood vessels. They achieve this by targeting a protein called vascular endothelial growth factor (VEGF). Bevacizumab, a well-known angiogenesis inhibitor, works by attaching to VEGF, preventing it from signaling cells to form new blood vessels. This essentially starves the tumor of the nutrients and oxygen it needs to grow.
How they are taken: Angiogenesis inhibitors like bevacizumab are typically given through an intravenous (IV) infusion. The frequency of these infusions usually ranges from every 2 to 3 weeks, depending on the specific drug and your treatment plan.
FDA-approved angiogenesis inhibitors for ovarian cancer include:
Yes, in some cases, your doctor might recommend a combination of treatments. For instance, bevacizumab (an angiogenesis inhibitor) and olaparib (a PARP inhibitor) can be taken together as maintenance therapy. This combination is often considered after initial chemotherapy and bevacizumab treatment, particularly if your cancer shows a response and is linked to a 'homologous recombination deficiency' (HRD) positive status. HRD means your cells struggle to repair double-strand DNA breaks, a situation that can be exacerbated by certain gene mutations like BRCA.
Like all medications, maintenance therapies can have side effects. It's important to discuss these openly with your doctor. They are experienced in managing these potential issues.
Your doctor can help manage these with prescribed medications for blood pressure control and nausea. Regular monitoring of your blood pressure and urine is also essential.
Low platelet counts can sometimes lead to bleeding. If your blood counts drop too low, your doctor might temporarily pause the PARP inhibitor treatment until your counts recover. Regular blood tests help monitor these levels closely.
Research and clinical trials have shown that maintenance therapy can significantly improve outcomes for ovarian cancer patients. By extending remission times and reducing the likelihood of recurrence, these therapies contribute to a longer progression-free survival (the time without cancer worsening) and, in many cases, can positively impact overall survival. The goal is not just to live longer, but to live better, with more time free from the burden of active cancer treatment.
It's vital to maintain open communication with your healthcare team throughout your treatment journey. You should contact your doctor immediately if you experience any of the following:
Your medical team is your greatest resource. Don't hesitate to ask questions, express your concerns, and share your experiences. Together, you can navigate the path forward with the best possible care.
The duration of maintenance therapy varies depending on the specific drug, the type of ovarian cancer, and how well you tolerate the treatment. It can range from several months to a couple of years. Your doctor will determine the optimal length of treatment for your individual case.
Yes, maintenance therapy is often recommended for recurrent ovarian cancer, especially if the cancer has responded well to previous platinum-based chemotherapy. Your doctor will assess your specific situation to see if maintenance therapy is an appropriate option for you.
If you miss a dose of an oral PARP inhibitor or other oral maintenance drug, follow the specific instructions provided by your doctor or pharmacist. Generally, you should take it as soon as you remember, unless it is almost time for your next scheduled dose. In that case, skip the missed dose and continue with your regular schedule. Do not double up on doses.
Maintenance therapy is designed to prevent recurrence and prolong remission, rather than to cure the cancer outright. It's a strategy to manage the disease long-term and improve quality of life.
Learn about potential side effects of CML treatments like TKIs, interferon, chemotherapy, and stem cell transplants. Understand what to expect and how to communicate with your doctor for effective management.
April 1, 2026
Discover essential support resources, financial aid options, and community connections for individuals navigating life with Chronic Myeloid Leukemia (CML). Find practical advice and empathetic guidance.
April 1, 2026
Explore targeted therapy for multiple myeloma. Learn how these precision treatments work, their types, potential side effects, and how they're used alongside other therapies to manage this blood cancer.
April 1, 2026